COMP <GO>
STLN vs AUNA // EV/EBITDA & P/E VALUATION
Starling Oncology Inc. (NASDAQ) VS. Auna SA (Class A) (NYSE) • 15-METRIC TALLY: STLN 2
— AUNA 0
■ METRIC PARITY
LAST: $6.65 (+0.15%) • MKT CAP: $677.7M
valuation
—
LAST: $4.80 (+1.27%) • MKT CAP: $355.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STLN VS. AUNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STLN | AUNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.10% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -7.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 27.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.58 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 29.8 | +19.70 | STLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $677.7M | $355.3M | $322.5M | STLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STLN REV | AUNA REV | STLN GROSS % | AUNA GROSS % | STLN FCF | AUNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.7M | — | — | — | -$27.8M | — |
| FY 2024 | $393.4M | — | — | — | -$30.3M | — |
| FY 2023 | $324.2M | — | — | — | -$36.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STLN // BETA —
AUNA // BETA —